Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.msard.2020.102120 http://scihub22266oqcxt.onion/10.1016/j.msard.2020.102120 32315980!7156942!32315980     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mult+Scler+Relat+Disord 2020 ; 42 (ä): 102120 Nephropedia Template TP {{tp|p=32315980|t=2020. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?|pdf=|usr=}}{{32315980}} gab.com Text COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role JO: Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=32315980 #FOAvip BACKGROUND: Coronavirus disease 19 (COVID-19) is a novel disease entity that is spreading throughout the world. It has been speculated that patients with comorbidities and elderly patients could be at high risk for respiratory insufficiency and death. Immunosuppression could expose infected patients to even higher risks of disease complications due to dampened immune response. However, it has been speculated that overactive immune response could drive clinical deterioration and, based on this hypothesis, several immunosuppressants are currently being tested as potential treatment for COVID-19. METHODS: In this paper we report on a patient that has been treated with ocrelizumab (a B-cell depleting monoclonal antibody) for primary progressive multiple sclerosis who developed COVID-19. RESULTS: Despite complete B cell depletion, patient symptoms abated few days after hospitalization, and he was discharged to home-quarantine. Phone interview follow-up confirmed that, after 14 days, no new symptoms occurred. DISCUSSION: This report supports the putative role of immunosuppressive therapy in COVID-19 affected patients. Twit Text FOAVip COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role ????Mult Scler Relat Disord http://www.kidney.de/pget.php?&tw=1&pmid=32315980 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32315980 #FOAvip English Wikipedia <ref>{{Cite pmid|32315980}}</ref> COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? #MMPMID32315980 Novi G; Mikulska M; Briano F; Toscanini F; Tazza F; Uccelli A; Inglese M Mult Scler Relat Disord 2020[Jul]; 42 (ä): 102120 PMID32315980show ga BACKGROUND: Coronavirus disease 19 (COVID-19) is a novel disease entity that is spreading throughout the world. It has been speculated that patients with comorbidities and elderly patients could be at high risk for respiratory insufficiency and death. Immunosuppression could expose infected patients to even higher risks of disease complications due to dampened immune response. However, it has been speculated that overactive immune response could drive clinical deterioration and, based on this hypothesis, several immunosuppressants are currently being tested as potential treatment for COVID-19. METHODS: In this paper we report on a patient that has been treated with ocrelizumab (a B-cell depleting monoclonal antibody) for primary progressive multiple sclerosis who developed COVID-19. RESULTS: Despite complete B cell depletion, patient symptoms abated few days after hospitalization, and he was discharged to home-quarantine. Phone interview follow-up confirmed that, after 14 days, no new symptoms occurred. DISCUSSION: This report supports the putative role of immunosuppressive therapy in COVID-19 affected patients. |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/complications/*physiopathology[MESH] |Humans[MESH] |Immunologic Factors/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Multiple Sclerosis, Chronic Progressive/complications/*drug therapy[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/*physiopathology[MESH] |Protective Factors[MESH] |SARS-CoV-2[MESH]COVID-19 in a MS patient treated with ocrelizumab: does immunosuppress(epmc).pdf DeepDyve Pubget Overpricing